abstract
purpos
determin
whether
procalcitonin
pct
level
could
help
discrimin
isol
viral
mix
bacteri
viral
pneumonia
patient
admit
intens
care
unit
icu
influenza
pandem
method
retrospect
observ
studi
perform
french
icu
pandem
level
pct
admiss
compar
patient
confirm
influenza
pneumonia
associ
associ
bacteri
coinfect
result
patient
confirm
infect
receiv
prior
antibiot
ci
document
bacteri
coinfect
mostli
caus
streptococcu
pneumonia
staphylococcu
aureu
fiftytwo
patient
pct
measur
admiss
includ
bacteri
coinfect
median
rang
valu
pct
significantli
higher
patient
bacteri
coinfect
versu
lgl
p
cutoff
lgl
sensit
specif
pct
distinguish
isol
viral
mix
pneumonia
respect
alveolar
condens
combin
pct
level
lgl
strongli
associ
bacteri
coinfect
new
pandem
influenza
viru
emerg
spread
global
high
rate
intens
care
unit
icu
admiss
among
hospitalis
patient
caus
death
includ
overwhelm
viral
infect
primari
secondari
bacteri
infect
presum
high
frequenc
bacteri
infect
hospitalis
patient
influenza
pneumonia
administ
antibiot
even
though
bacteri
coinfect
consid
unlik
inde
bacteri
pneumonia
differenti
viral
pneumonia
basi
patient
characterist
chest
radiograph
find
routin
laboratori
result
procalcitonin
pct
recognis
marker
bacteri
infect
might
prognost
marker
lower
respiratori
tract
infect
studi
assess
pct
level
viral
infect
except
paediatr
studi
pct
found
help
distinguish
viral
bacteri
mening
pneumonia
small
studi
singapor
coronaviru
outbreak
suggest
pct
remain
low
level
viral
infect
studi
aim
examin
whether
pct
level
may
help
discrimin
viral
mix
bacteri
viral
pneumonia
among
patient
present
icu
sever
communityacquir
pneumonia
influenza
pandem
observ
multicentr
studi
conduct
conjunct
revagrippesrlf
registri
set
franc
novemb
april
record
patient
sever
influenza
infect
admit
icu
among
particip
centr
volunt
particip
substudi
complet
specif
case
report
form
whether
diagnosi
bacteri
coinfect
establish
centr
routin
perform
measur
pct
andor
creactiv
protein
crp
level
biomark
level
record
analys
present
studi
microbiolog
investig
biomark
level
obtain
part
routin
clinic
manag
patient
discret
treat
physician
studi
approv
ethic
review
board
de
de
langu
inform
consent
waiv
patient
confirm
diagnosi
influenza
infect
pcr
nasopharyng
secret
bronchoalveolar
lavag
fluid
associ
clinic
pattern
communityacquir
pneumonia
defin
associ
acut
onset
clinic
symptom
cough
fever
dyspnoea
compat
infiltr
chest
radiograph
absenc
altern
diagnosi
elig
studi
better
distinguish
patient
without
bacteri
coinfect
admiss
analysi
select
patient
receiv
antibiot
prior
icu
admiss
exclud
patient
suspect
hospitalacquir
influenza
infect
document
nonpulmonari
bacteri
infect
sever
immunocompromis
patient
demograph
clinic
microbiolog
data
obtain
within
first
h
icu
admiss
collect
retrospect
confirm
bacteri
pulmonari
infect
obtain
blood
cultur
urinari
antigen
pneumococc
legionella
test
cultur
respiratori
tract
secret
sampl
patient
thu
categoris
associ
bacteri
coinfect
level
biomark
compar
two
subgroup
procalcitonin
assay
use
timeresolv
amplifi
cryptat
emiss
technolog
kryptor
analys
brahm
diagnostica
berlin
germani
function
assay
detect
concentr
lgl
total
pct
assay
imprecis
report
manufactur
lgl
less
lgl
fisher
exact
test
use
compar
proport
categor
variabl
continu
variabl
student
test
mannwhitney
u
test
use
compar
parametr
nonparametr
data
respect
diagnost
accuraci
biomark
examin
receiveroper
curv
roc
statist
analys
perform
pasw
statist
spss
inc
chicago
usa
substudi
french
revasrlf
influenza
registri
conduct
centr
data
patient
without
diagnosi
bacteri
coinfect
record
patient
exclud
analysi
base
predefin
exclus
criteria
exclud
administr
antibiot
prior
icu
admiss
thu
patient
form
main
cohort
document
bacteri
coinfect
associ
influenza
infect
tabl
microorgan
identifi
includ
streptococcu
pneumonia
n
staphylococcu
aureu
n
group
streptococcu
n
microorgan
n
recov
blood
cultur
n
andor
respiratori
tract
secret
specimen
n
includ
bronchoalveolar
lavag
n
protect
distal
sampl
n
andor
urinari
antigen
test
n
tabl
compar
admiss
characterist
two
subgroup
patient
without
bacteri
coinfect
former
subgroup
less
often
comorbid
vs
p
higher
sap
score
vs
p
often
alveolar
condens
chest
xray
vs
p
overal
mortal
icu
patient
differ
without
bacteri
coinfect
vs
respect
patient
bacteri
coinfect
often
requir
invas
mechan
ventil
vs
ci
p
longer
length
stay
icu
median
vs
day
p
pct
crp
level
obtain
respect
patient
biomark
measur
simultan
patient
pct
level
measur
admiss
document
bacteri
coinfect
associ
influenza
infect
mostli
caus
streptococcu
pneumonia
staphylococcu
aureu
median
iqr
pct
level
icu
admiss
significantli
higher
patient
bacteri
coinfect
iqr
lgl
versu
iqr
lgl
p
fig
cutoff
lgl
identifi
bacteri
coinfect
sensit
specif
neg
predict
valu
area
roc
curv
auroc
diagnos
bacteri
coinfect
use
pct
ci
pct
level
less
lgl
combin
lack
alveolar
condens
strongli
associ
absenc
bacteri
coinfect
ci
p
mortal
icu
among
subgroup
pct
level
lgl
associ
sever
outcom
invas
ventil
andor
death
icu
ci
p
patient
crp
level
measur
without
bacteri
coinfect
median
interquartil
rang
valu
respect
p
ranksum
test
patient
biomark
level
fig
report
patient
sever
influenza
pneumonia
almost
onehalf
bacteri
coinfect
document
absenc
prior
antibiot
administr
coinfect
caus
streptococcu
pneumonia
patient
pct
measur
found
pct
level
lgl
discrimin
well
isol
viral
mix
bacteri
viral
pneumonia
experi
use
biomark
diagnost
adjunct
influenza
pneumonia
limit
studi
describ
abil
pct
crp
discrimin
viral
bacteri
infect
includ
patient
influenza
sever
diseas
metaanalysi
conclud
pct
accur
crp
distinct
viral
bacteri
infect
ingram
et
al
suggest
pct
level
assist
discrimin
sever
lower
respiratori
tract
infect
bacteri
viru
origin
result
suggest
combin
low
level
pct
lack
alveolar
infiltr
chest
radiograph
make
bacteri
coinfect
unlik
patient
present
sever
viral
pneumonia
pct
emerg
diagnost
biomark
estim
likelihood
bacteri
infect
tailor
antimicrobi
therapi
howev
prognost
valu
less
clear
critic
ill
patient
high
maximum
pct
level
pct
increas
day
independ
predictor
allcaus
mortal
patient
legionella
pneumonia
haeuptl
et
al
found
high
accuraci
initi
serial
pct
level
predict
mortal
need
icu
admiss
high
pct
level
associ
seri
bacteri
coinfect
sever
outcom
mechan
ventil
andor
death
previou
studi
patient
influenza
pneumonia
report
rate
bacteri
coinfect
rang
patient
similar
rate
report
pandem
season
proport
may
actual
underestim
common
administr
antibiot
prior
hospit
icu
admiss
overal
almost
onehalf
patient
document
bacteri
coinfect
exclud
receiv
prior
antibiot
clearli
much
higher
rate
record
season
influenza
similarli
experi
argentina
presenc
bacteri
coinfect
associ
seri
sever
diseas
limit
studi
includ
rel
small
sampl
size
lack
repeat
pct
measur
true
proport
patient
bacteri
coinfect
influenza
pneumonia
also
difficult
ascertain
howev
exclud
patient
receiv
prior
antibiot
thu
allow
accur
diagnosi
bacteri
infect
believ
come
closer
estim
frequenc
influenc
bacteri
coinfect
patient
sever
influenza
pneumonia
pct
level
appear
discrimin
well
patient
bacteri
coinfect
influenza
pneumonia
despit
small
sampl
patient
seri
measur
pct
crp
obtain
pct
level
appear
accur
discrimin
viral
mix
viral
bacteri
infect
among
patient
present
communityacquir
pneumonia
suspect
viral
origin
influenza
epidem
summari
bacteri
coinfect
like
affect
almost
onehalf
patient
sever
influenza
pneumonia
associ
sever
outcom
measur
pct
level
admiss
help
discrimin
patient
bacteri
coinfect
isol
viral
pneumonia
clinic
trial
differ
set
establish
pct
safe
use
help
decid
upon
initi
durat
antibiot
therapi
thu
potenti
help
reduc
antibiot
overus
combin
clinic
judgment
influenza
epidem
low
pct
level
may
identifi
subgroup
patient
empir
antibiot
therapi
may
withheld
withdrawn
earli
